**VPA10454/078/001**

**TUR-3 emulsion for injection for turkeys**

| Variation | Summary | Date |
|---|---|---|
| Vet - B3 u) | VNRA - Vet - B3 u) - - Vet - B3 u) - Changes to the quality part of the dossier: Deletion of a Ph. Eur. Transmissible Spongiform Encephalopathy (TSE) CEP — for an active substance;— for a starting material, reagent or intermediate of an active substance;— for an excipient | 02/10/26 |
| Vet - A1 b) | VNRA - Vet - A1 b) - b) Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. - A1 b) Administratvie changes: Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. | 02/08/24 |
| Vet - B21 | VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product | 15/11/23 |
| Vet - B43 | VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible | 10/11/23 |
| Vet - C1 | VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) | 15/03/23 |
| Vet - F.I.a.1 d) | VRA-S - Vet - F.I.a.1 d) - d) The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - F.I.a.1 d) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a | 16/12/22 |

| | | |
|---|---|---|
| | biological/immunological product | |
| Vet - F.I.a.2 z) | VRA-S - Vet - F.I.a.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.2 z) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 | 03/08/22 |